Thomas Bhatt

Thomas Bhatt focuses on low-grade serous ovarian carcinoma (LGSOC), a distinct and underserved histologic subtype driven by MAPK pathway activation. His research contributed to clinical studies of MEK inhibitors including binimetinib and trametinib in LGSOC, which led to first-line MEK inhibitor approval. He has also studied the role of hormonal therapy in LGSOC and its prolonged natural history requiring distinct management from high-grade serous disease. His work established LGSOC as a molecular subtype requiring separate clinical trial design.